Hutter, P. J. King and R. D. Shillito, Experientia Supplementum 46, 1983, p. 19.
13. Sinha, R. R., Das, K. and Sen, S. K., *Indian J. Exp. Biol.*, 1983, **21**, 113.
14. Niizeki, M. and Grant, W. F., *Can. J. Bot.*, 1971, **49**, 2041.
15. Konar, R. N. and Nataraja, K., *Phytomorphology*, 1965, **15**, 245.
16. Sinha, R. R., *Application of plant cell culture techniques in certain pulse crops*, Ph.D. Thesis, Calcutta University, 1980.
17. Morel, G., Martin, C. and Muller, J. F., *Ann. Physiol. Veg.*, 1968, **10**, 113.
18. Pillai, S. K. and Hildebrandt, A. C., *Am. J. Bot.*, 1969, **56**, 52.
19. Kartha, K. K., Michayluk, M. R., Kao, K. N., Gamborg, O. L. and Constabel, F., *Plant Sci. Lett.* 1974, **3**, 265.

ANNOUNCEMENTS

SECOND INTERNATIONAL SYMPOSIUM ON BENEFICIATION AND AGGLOMERATION ISBA '86

The Regional Research Laboratory (CSIR) Bhubaneswar in association with the Bhubaneswar Chapter, Indian Institute of Metals have organised the Second Symposium on beneficiation and agglomeration of minerals during *December 17–19, 1986.*

Original papers relating to any of the following topics are invited: 1. Mineral characterisation of very fine particles, 2. Recent developments in techniques and methods for mineral processing for the recovery of fine particles and their agglomeration. 3. Pilot plant and plant experiences in processing of low grade ores, ore fines and concentrates. 4. Techniques and processes towards energy conservation in mineral processing and agglomeration. 5. Developments in the area of treatment of mining and metallurgical wastes. 6. Characterisation of agglomerates.

Details can be had from D. N. Dey, Convener, ISBA-86, Regional Research Laboratory, Bhubaneswar 751 013, India.

INFLUENZA VACCINES FOR 1986–1987—MODIFIED COMPOSITION RECOMMENDED

A change in the composition of the influenza vaccine is now recommended by representatives of the World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza. The current composition has been used since 1984 and during the consultation, held in mid-February in Geneva, experts recommended that the vaccine for use in the 1986–1987 season should be trivalent and contain the following antigens:

- an A/Christchurch/4/85(H3N2)-A/Mississippi/1/85(H3N2)-like antigen
- an A/Chile/1/83(H1N1)-like antigen, and
- a B/Ann Arbor/1/86-like antigen

Details of the influenza epidemiology, antigenic and vaccine studies leading to the recommendations for the influenza vaccine appear in the WHO *Weekly Epidemiological Record*, No. 9, (WHO Press Release, No. 7, 28 February 1986; World Health Organization, Media Service, 1211, Geneva, 27; Switzerland)